Corlux plus Risperdal results in less abdominal fat
The USA's Corcept Therapeutics has reported detailed results from a study showing that Corlux (mifepristone) mitigates the weight gain and other metabolic effects associated with Johnson & Johnson's atypical antipsychotic Risperdal (risperidone).
The company previously announced top-line data and it has now also revealed findings showing that Corlux plus Risperdal results in less abdominal fat, lower fasting insulin levels and lower triglyceride levels - all of which were statistically significant compared to treatment with Risperdal alone.
There was an increase in abdominal fat (as measured by waist circumference) of 3.57cm in the Risperdal alone arm, compared to 2.03cm in the Risperdal plus Corlux group (p<0.05). Fasting insulin increased by 10.97 mU/L in the Risperdal alone cohort, compared to 1.80 mU/L in the Risperdal plus Corlux group (p<0.05).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze